![]() – Table 22-1: Myeloma Working Group criteria for assessing response in monoclonal plasma cell proliferative diseases using FLC analysis – Table 22-1: International Myeloma Working Group response criteria for multiple myeloma – Table 22-16: Prognostic factors in multiple myeloma – Table 22-15: Investigations for the diagnosis and differentiation of monoclonal plasma cell proliferative diseases – Staging: Table 22-14: Staging system for multiple myeloma – Solitary plasmocytoma of the bone: Table 22-24: Findings in clonal plasma cell proliferative disorders – Non secretory myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – Light chain myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – IgM myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – IgG myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – IgE myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – IgD myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – IgA myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders – Extramedullary myeloma: Table 22-24: Findings in clonal plasma cell proliferative disorders ![]() ![]() – Table 22-11: Risk of progression from MGUS to symptomatic multiple myeloma within 20 years Monoclonal gammopathy of undetermined significance (MGUS) – Pseudo M-gradient: Table 22-5: Pseudo M-gradients that may be mistaken for M-gradients in serum protein electrophoresis – Plasma cell proliferative disorder: Table 22-24: Findings in clonal plasma cell proliferative disorders – Proliferative glomerulonephritis with monoclonal Ig deposits: Table 22-20: Monoclonal gammopathies of renal significance – Monoclonal immunoglobulin deposition disease: Table 22-20: Monoclonal gammopathies of renal significance – Immunotactoid nephropathy: Table 22-20: Monoclonal gammopathies of renal significance – Table 22-24: Findings in clonal plasma cell proliferative disorders – μ-HCD: Table 22-24: Findings in clonal plasma cell proliferative disorders ![]() – γ-HCD: Table 22-24: Findings in clonal plasma cell proliferative disorders – α-HCD: Table 22-24: Findings in clonal plasma cell proliferative disorders – Type-II cryoglobulinemia: Table 22-20: Monoclonal gammopathies of renal significance – Type-I-cryoglobulinemia: Table 22-20: Monoclonal gammopathies of renal significance – Table 22-20: Monoclonal gammopathies of renal significance – IgM amyloidosis: Table 22-24: Findings in clonal plasma cell proliferative disorders – AL (AH and ALH) amyloidosis: Table 22-26: Findings in amyeloidosis 13 Homocysteine, vitamin B 12, folates, vitamin B 6, choline, betaineġ4 Gastrointestinal and pancreatic functionġ7 Thrombocytopenias and thrombocyte function testingĢ2 Multiple myeloma and related plasma cell proliferative disordersĢ4 Laboratory and clinical assessment of the complement systemĢ6 Immunogenetics: clinical and diagnostic aspects of the Human leukocyte antigen (HLA) systemĢ9 Cancer associated syndromes (para neoplastic syndromes)ģ1 Renin-angiotensin-aldosterone system (RAS)ģ2 Pheochromocytoma, paraganglioma, neuroblastomaģ4 Disorders of the pituitary-adrenocortical axisģ5 Disorders of the pituitary-somatotroph axisģ7 Disorders of the hypothalamic-pituitary-gonadal axisĤ6 Laboratory diagnosis of neurological diseasesĥ0 Standardization and quality assurance of quantitative determinationsĥ1 Effect of physical exercise on laboratory test resultsĥ2 Selected analytical laboratory techniquesĢ2.1 B cell development and proliferationĢ2.3 Laboratory diagnostics of monoclonal gammopathyĢ2.3.1 Serum protein electrophoresis (SPE)Ģ2.3.3 Serum immunofixation electrophoresis (IFE)Ģ2.3.3.1 Urine immunofixation electrophoresisĢ2.3.4 Immunosubtraction and capillary zone electrophoresis (CZE)Ģ2.3.6 Quantitative determination of immunoglobulin isotypesĢ2.4 Multiple myeloma (MM), precursor stages of MM and other plasma cell proliferative disordersĢ2.4.1 Monoclonal gammopathy of undetermined significance (MGUS)Ģ2.4.3.1.1 Basic tests used to assess whole body statusĢ2.4.3.1.3 Assessment of myeloma related tissue damageĢ2.4.3.1.4 Prognosis and risk stratificationĢ2.5 Treatment of newly diagnosed multiple myelomaĢ2.5.1 Laboratory tests for myeloma managementĢ2.7 Monoclonal gammopathy of renal significance (MGRS)Ģ2.7.2 Multiple myeloma with central nervous system involvementĢ2.7.3 Multiple myeloma related polyneuropathyĢ2.10 Findings in clonal plasma cell proliferative disorders ![]()
0 Comments
Leave a Reply. |